Paroxysmal Nocturnal Hemoglobinuria Treatment Market Analysis

Treatment Type (Complement Inhibitors, Iron Therapy, Immunosuppressant Drugs, Bone Marrow Transplantation, Other Treatment Types)

By treatment type, the complement inhibitors segment is likely to account for around 36.1% paroxysmal nocturnal hemoglobinuria (PNH) treatment market share by 2037. The segment’s growth is attributed to the primary treatment type for PNH. Complement inhibitor therapies allow patients to improve their quality and life and reduce the need for blood transfusions, contributing to the rapid growth of the segment. Ongoing approval of add-on therapies along with complement inhibitors like ravulizumab is positioned to maintain the growth curve of the segment. For instance, in April 2024, Voydeya (Danicopan) was approved in the U.S. as an add-on therapy to ravulizumab or eculizumab for the treatment of adults diagnosed with PNH.

The iron therapy treatment type segment of the global paroxysmal nocturnal hemoglobinuria treatment sector is poised to register a robust growth curve during the forecast period owing to increasing application to treat patients experiencing chronic hemolysis leading to iron deficiency. Iron supplementation can be essential in addressing anemia caused due to the breakdown of red blood cells in patients diagnosed with PNH. For instance, as per the American Society of Hematology, pregnant women diagnosed with PNH have a greater need for iron supplementation owing to intravascular hemolysis, and in certain cases, PNH patients may require intravenous iron during pregnancy. The rising awareness of PNH treatments and early diagnosis is poised to boost the application of iron therapy to support additional complications in patients suffering from PNH.

Route of Administration (Parenteral, Oral)

By route of administration, the parenteral segment of the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market is projected to increase its revenue share by the end of the forecast period. The growth of the segment is owed to applications in complement inhibitors such as ravulizumab and eculizumab. The parenteral route of administration ensures effective absorption providing immediate benefits in managing life-threatening complications. Additionally, pharmaceutical companies are seeking to improve patient convenience by releasing novel therapeutics such as crovalimab that patients can self-administer. For instance, in October 2023, the FDA approved pegcetacoplan (Empaveli) on-body injector for self -administration in PNH treatment. Trends indicate developments in subcutaneous formulations that are positioned to continue the robust growth of this segment.

Our in-depth analysis of the global paroxysmal nocturnal hemoglobinuria (PNH) treatment market includes the following segments: